Literature DB >> 21536240

Translocation t(7;19)(q22;q13)−a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma?

Domenico Trombetta1, Linda Magnusson, Fredrik Vult von Steyern, Jason L Hornick, Christopher D M Fletcher, Fredrik Mertens.   

Abstract

Pseudomyogenic hemangioendothelioma is a recently described morphologic entity among soft tissue tumors. It is more common in young individuals, shows a male predominance, is often multifocal and involves different tissue planes, and shows a high propensity for local recurrence. To our knowledge, no genetic characteristics of this tumor type have been presented before. Here, we describe the finding of a balanced t(7;19)(q22;q13) as the sole anomaly in three lesions from a 14-year-old girl. By means of fluorescence in situ hybridization, the breakpoints could be delineated, but reverse transcriptase−polymerase chain reaction for putative fusion genes did not reveal any fusion transcript. Interphase fluorescence in situ hybridization on sections from nine other pseudomyogenic hemangioendotheliomas indicated the presence of an unbalanced der(7)t(7;19) in one of them. Thus, the translocation between chromosomes 7 and 19 seems to be a recurrent phenomenon and is likely to be of pathogenetic significance in at least a subset of pseudomyogenic hemangioendotheliomas.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21536240     DOI: 10.1016/j.cancergen.2011.01.002

Source DB:  PubMed          Journal:  Cancer Genet


  22 in total

1.  Pseudomyogenic hemangioendothelioma (epithelioid sarcoma-like hemangioendothelioma, fibroma-like variant of epithelioid sarcoma) of the thoracic spine.

Authors:  Michael McGinity; Viktor Bartanusz; Bradley Dengler; Lee Birnbaum; James Henry
Journal:  Eur Spine J       Date:  2013-02-24       Impact factor: 3.134

2.  A novel treatment for bone lesions of multifocal epithelioid sarcoma-like hemangioendothelioma.

Authors:  Adrian T Davis; A Mary Guo; Nancy J Phillips; David D Greenberg
Journal:  Skeletal Radiol       Date:  2015-01-08       Impact factor: 2.199

Review 3.  What is new in endothelial neoplasia?

Authors:  David J Papke; Jason L Hornick
Journal:  Virchows Arch       Date:  2019-08-28       Impact factor: 4.064

4.  Pseudomyogenic Hemangioendothelioma: A Vascular Tumor Previously Undescribed in the Oral Cavity.

Authors:  Yeshwant B Rawal; Kenneth M Anderson; Thomas B Dodson
Journal:  Head Neck Pathol       Date:  2016-11-22

5.  Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five cases.

Authors:  M Fernanda Amary; Paul O'Donnell; Fitim Berisha; Roberto Tirabosco; Tim Briggs; Rob Pollock; Adrienne M Flanagan
Journal:  Skeletal Radiol       Date:  2013-02-05       Impact factor: 2.199

Review 6.  Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.

Authors:  Adrián Mariño-Enríquez; Judith V M G Bovée
Journal:  Surg Pathol Clin       Date:  2016-09

7.  Oral Pseudomyogenic Hemangioendothelioma: Case Report and Review of the Literature.

Authors:  Austin J Shackelford; Carleigh R Canterbury; Michael A Perrino; Joseph Wang; Elizabeth M Philipone; Scott M Peters
Journal:  Head Neck Pathol       Date:  2020-02-03

8.  Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions.

Authors:  Narasimhan P Agaram; Lei Zhang; Paolo Cotzia; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-12       Impact factor: 6.394

9.  Primary pseudomyogenic haemangioendothelioma of bone: report of two cases.

Authors:  Alberto Righi; Marco Gambarotti; Piero Picci; Angelo Paolo Dei Tos; Daniel Vanel
Journal:  Skeletal Radiol       Date:  2014-10-11       Impact factor: 2.199

Review 10.  Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.

Authors:  Mark Linch; Aisha B Miah; Khin Thway; Ian R Judson; Charlotte Benson
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.